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Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II–
IV (group B) and stage I (group C) without liver metastasis were analysed. MAGE-A protein expression was evaluated by
immunohistochemistry using a 6C1 monoclonal antibody and MAGE-A10 mRNA expression was detected by highly sensitive in situ
hybridisation using a cRNA probe. Expressions of MAGE-A protein and MAGE-A10 mRNA in group A were detected in 65.9 and
80.5%, respectively. Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and
C (0, 0%) (P¼0.0003, P¼o0.0001, respectively). MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out
of nine patients. The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary
sites was 81.7% (Po0.0001). MAGE-A10 gene expression was associated with reduced survival duration. The results of this study
suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.
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Stomach cancer is one of the most common worldwide malignant
neoplasms (Dicken et al, 2005). Although its incidence is
decreasing, it is the second most common cancer in Japan after
lung cancer and contributes to the burden of cancer death (Inoue
and Tsugane, 2005). The presence of distant metastasis is an
independent prognostic factor (Siewert et al, 1998). In particular,
patients with liver metastasis had shown a poor prognosis in spite
of combined therapy (Sarela et al, 2006). Therefore, further study
to understand the molecular changes associated with stomach
cancer especially when tumour progresses needs to be undertaken
to introduce treatment strategies. Furthermore, the mechanism of
liver metastasis should be elucidated, as it may present a clue to
predict and subsequently treat patients with liver metastasis.
It has been reported that MAGE-A family genes located at
chromosome Xq28 are expressed in malignant tumours, whereas
they are not expressed in adult tissue except the testis and
placenta. Of the MAGE-A family, MAGE-A1, -A3, -A6 and -A10
encode tumour antigens recognised by autologous cytotoxic T cells
(CTL) (De Plaen et al, 1994). A CTL clone that could lyse
autologous melanoma cells significantly produced tumour necrosis
factor on stimulation with HLA-A2 MAGE-A10-expressing cells
(Huang et al, 1999). Only CTL recognising the antigenic peptide
with high efficiency can lyse the tumour cells expressing the
cancer/testis (CT) antigens. Thus, these antigens may be suitable
targets for active immunotherapy in malignant tumours such as
melanoma (Dutoit et al, 2001, 2002; Ayyoub et al, 2003).
In stomach cancer, MAGE-A protein expression was detected in
only 15.8% of the samples, and correlated with lymph node
metastasis, advanced stage of the disease and a worse prognosis
(Jung et al, 2005). However, MAGE-A protein was expressed at
lower levels in metastatic lymph nodes from stomach cancer than
in the primary lesions (Sadanaga et al, 1999). The frequency of
MAGE-A1, -A2 and -A3 gene expression was reported to be 41, 31
and 38% in the primary lesion, respectively (Inoue et al, 1995).
About 74% of the tumours expressed at least one CT antigen, most
frequently MAGE-A3, -A4 and NY-ESO-1. However, MAGE-A gene
expression did not correlate with clinicopathologic findings of the
tumours (Wang et al, 2004). MAGE-A10 expression was reported
to be low in the primary lesion and had no correlation with the
clinicopathology of the tumours (Li et al, 1997). There have been
no reports on the expression of the MAGE-A10 gene in metastatic
lesions in patients with stomach cancer.
In this study, the MAGE-A family protein expression was
detected by immunohistochemistry using the mouse monoclonal
antibody 6C1, which cross-reacted with MAGE-A1, -A3, -A4, -A6,
-A10 and -A12 (Rimoldi et al, 2000). Furthermore, to clarify the
distribution of MAGE-A10 mRNA expression in stomach cancer
tissue, the highly sensitive in situ hybridisation (ISH) using cRNA
probes that enabled us to detect even the low-copy gene expression
in clinical samples was performed. Our objective was to assess the Revised 4 June 2008; accepted 4 June 2008; published online 1 July 2008
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in the progression of stomach cancer and to elucidate suitable
patients for active immunotherapy using MAGE-A10 peptide.
MATERIALS AND METHODS
Tumour samples
Formalin-fixed and paraffin-embedded tissues were obtained from
a series of 71 patients who had undergone gastrectomy for stomach
cancer at the Tama-Nagayama Hospital, Nippon Medical School.
In five unresectable cases, biopsy specimens were used. The
patients were divided into three groups. Group A consisted of 41
patients with liver metastasis occurring within 3 years after the
operation: synchronous metastasis (stage IV) in 23 cases and
metachronous metastasis (stages I–IV) in 18 cases. In group A,
nine hepatectomised specimens (synchronous in six, metachro-
nous in three) were used, in addition to the primary sites. Groups
B and C consisted of 15 patients each with stages II–IV and stage I
without liver metastasis. The final stage and histopathologic
findings are defined according to the Japanese Classification of
Gastric Carcinoma (Japanese Gastric Cancer Association, 1998).
Patients’ characteristics and pathologic findings are listed in
Table 1. Informed consent was obtained from all patients. The
study was approved by the Institutional Review Board of Tama-
Nagayama Hospital, Nippon Medical School.
Immunohistochemistry
The sections were deparaffinised in xylene and hydrated through
descending ethanol series and water. Antigen retrieval was
performed with the DAKO Target Retrieval Solution (DAKO,
Glostrup, Denmark) for 40min at 981C. Endogenous peroxidase
blocking was performed with 0.3% hydrogen peroxide in
methanol. After incubation with the mouse monoclonal anti-
MAGE-A antibody 6C1 (Neo-Markers, Fremont, CA, USA) for
30min at room temperature, DAKO ENVISION Plus detection was
applied for 30min at room temperature. Then, diaminobenzidine
was dropped as a chromogen. The slides were counterstained with
haematoxylin and mounted.
In situ hybridisation
Preparation of the cRNA probes Total RNA was extracted from
LCN1 cells derived from neuroendocrine carcinoma of the lung
(Jiang et al, 2004) with Isogen (Nippon Gene, Tokyo, Japan)
according to the manufacturer’s instructions and reverse tran-
scribed with the First Strand cDNA Synthesis Kit for RT–PCR
(Roche Diagnostics, Mannheim, Germany). Primer sequences used
in this study against MAGE-A10 mRNA have been described
previously (Peng et al, 2005). Digoxigenin (DIG)-labelled sense
and antisense cRNA probes were generated by T7 RNA polymerase
promoter region-tailed PCR followed by in vitro transcription with
T7 RNA polymerase using a DIG in vitro transcription kit (Roche
Diagnostics) described in detail previously by Tanizaki et al
(2006).
Highly sensitive in situ hybridisation The ISH was carried out as
described previously (Yoshikawa et al, 2007). In brief, deparaffi-
nised 4-mm-thick sections were treated with 10mgml
 1 proteinase
K (Roche Diagnostics) for 20min at 371C. The sections were post-
fixed in 4% paraformaldehyde and treated with 0.2 N HCl and
0.25% acetic anhydride in 0.1 M tri-ethanol amine (pH 8.0) for
10min each. After treatment with 3% hydrogen peroxide for
60min, the sections were dehydrated and air-dried. A 50ml portion
of the hybridisation mixture (mRNA In-situ Hybridization
Solution) (DAKO) with 10ng sense or antisense cRNA probe was
loaded onto each section and hybridised for 16–18h at 501C. After
hybridisation, the sections were washed in 2  standard sodium
citrate (SSC)/50% formamide for 30min at 551C and treated with
10mgml
 1 RNase A (Roche Diagnostics) for 30min at 371C and
stringently washed with 2  SSC, 0.2  SSC and 0.1  SSC for
20min each at 551C. After being placed into 0.01 M Tris-HCl pH
7.5, 0.3 M NaCl and 0.1% Tween 20 (TBS-2T) three times for 5min
each, and in 0.5% casein/0.01 M Tris-HCl pH 7.5 and 0.15 M NaCl
for 10min, the sections were reacted with 400 times diluted
horseradish peroxidase (HRP)-conjugated rabbit anti-DIG Fab0
fragmented polyclonal antibody (DAKO), 0.07mmoll
 1 biotiny-
lated tyramide and 500 times diluted HRP-conjugated streptavidin
(DAKO) for 15min each. Finally, the sections were visualised with
DAB solution (DAB Substrate Kit) (DAKO) and counterstained
with Mayer’s haematoxylin. Thereafter, sections were mounted
with Pristine Mount (Invitrogen, Carlsbad, CA, USA).
Scoring of immunohistochemistry and in situ
hybridisation
Evaluation of tumour cells in each sample was scored as 0, 1, 2 or
3, corresponding to absent, weak, moderate or intense staining,
respectively. The intensity of the cells scoring moderate or higher
was judged as positive. The tissues consisting of more than 30%
positive tumour cells were considered significant.
Statistical analysis
Fisher’s exact test, Kaplan–Meier survival analysis and log-rank
test for univariate analysis were performed using the Statview 5.0
software (Abacus System, Berkeley, CA, USA). P-valueso0.05 were
considered significant.
RESULTS
MAGE-A protein and MAGE-A10 mRNA expression in the
primary lesion
The incidence of MAGE-A protein expression was 65.9% (27 cases)
in group A, 6.7% (1 case) in group B and 0% in group C. Although
both nucleus and cytoplasm were stained against 6C1 in most of
the cases, in some cases the nucleus was dominantly stained
(Figure 1A and 1B). No positive staining was found in any of the
non-cancerous tissues (Figure 1C). Of 28 cases positive for 6C1, the
distribution of positively stained cells showed a diffuse pattern in
67.9% (19 cases) and a focal pattern in 32.1% (9 cases). The
Table 1 Patients’ characteristics in each group
Group A Group B Group C
Age (years)
Median (range) 70 (47–90) 63 (43–77) 66 (30–77)
Gender
Male/female 37/4 11/4 10/5
Stage
IA 1 — 15
IB 1 — 0
II 5 8 —
IIIA 4 4 —
IIIB 6 2 —
IV 24 (23)
a 1—
Histology
Differentiated
b 25 4 8
Undifferentiated
c 16 11 7
aSynchronous liver metastasis.
btub1, tub2.
cpor1, por2, sig.
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than that in groups B and C (P¼0.0001 and Po0.0001,
respectively).
The incidence of MAGE-A10 mRNA expression was 80.5% (33
cases) in group A, 26.7% (4 cases) in group B and 0% (none) in
group C. No positive staining was observed with the sense cRNA
probe. Figure 1D and 1E presents a case with MAGE-A10 mRNA
expression in the primary site (case 13). No positive staining was
observed in any of the non-cancerous tissues (Figure 1F). Further,
no positive staining was observed with the sense cRNA probe.
Figure 1 A case with synchronous liver metastasis (case 13). At the primary site, (A) MAGE family proteins were observed in the nuclei of tumour cells
( 80). (B) High-power view of (A). They were dominantly and homogeneously localised in the nuclei of tumour cells ( 200). (C) At the normal gastric
mucosa, MAGE family proteins were not observed ( 80). (D) MAGE-A10 mRNA signals were coincidently observed in MAGE family protein-positive
tumour cells ( 80). (E) High-power view of (D). They were abundant in the cytoplasm of tumour cells ( 200). (F) At the normal gastric mucosa,
MAGE-A10 mRNA signals were not found ( 80).
Table 2 Correlation of 6C1 and MAGE-A10 mRNA expression and rate
of concordance in each group
Group A Group B Group C
6C1 (+)/MAGE-A10 (+) 25 1 0
6C1 (+)/MAGE-A10 ( )2 0 0
6C1 ( )/MAGE-A10 (+) 8 3 0
6C1 ( )/MAGE-A10 ( ) 6 11 15
Total 41 15 15
Rate of concordance (%) 75.6 80 100
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B and C (P¼0.0003 and Po0.0001, respectively). MAGE-A10
mRNA expression with liver metastasis was more frequent in
87.0% of synchronous metastasis compared with 72.2% of
metachronous metastasis. However, no statistical significance
was observed. The association of the expression of MAGE-A
protein and MAGE-A10 mRNA is listed in Table 2. Of 37 cases with
MAGE-A10 mRNA expression, 70.3% (26 cases) were positive for
MAGE-A protein. The rates of concordance between MAGE-A
protein expression and MAGE-A10 mRNA expression were 75.6%
in group A, 80.0% in group B and 100% in group C. Totally, the
rate of concordance was 81.7% (Po0.0001).
MAGE-A protein expression and MAGE-A10 mRNA
expression in liver metastasis
In nine cases of hepatectomy or liver biopsy for metastatic lesions,
positive expressions were detected in seven (77.8%) for MAGE-A
protein and eight (88.9%) for MAGE-A10 mRNA (Table 3). Two
cases in the positive MAGE-A10 mRNA group were negative for
6C1 expression (cases 16 and 21). Both MAGE-A protein and
MAGE-A10 mRNA expressions in hepatic tissue with a synchro-
nous liver metastasis (case 7) are shown in Figure 2.
MAGE-A protein expression and MAGE-A10 mRNA
expression in alpha fetoprotein-producing stomach cancer
Of five cases with alpha fetoprotein (AFP) producing stomach
cancer proved by serum concentration and immunohistochemistry,
MAGE-A protein expression and MAGE-A10 mRNA expression
were found in three cases (60.0%) and five cases (100%),
respectively. Five cases of positive MAGE-A10 mRNA expression
were intensely and diffusely stained in the tumour cells. Figure 1
presents a case with AFP-producing stomach cancer expressing
MAGE-A protein and MAGE-A10 mRNA (case 13).
Survival analysis
Kaplan–Meier analysis revealed that group A had significantly
shorter survival duration than groups B and C (Po0.0001, each). A
Table 3 Expression of 6C1 and MAGE-A10 mRNA in hepatectomised
patients
Primary Liver
Case 6C1 MAGE-A10 6C1 MAGE-A10
1 M ++++
2M   +   +
7 S ++++
1 2 S ++++
1 6 M +++ 
1 7 S ++++
21 S   +++
2 8 S ++++
41 S   +   +
M¼metachronous liver metastasis; S¼synchronous liver metastasis.
Figure 2 A case with synchronous hepatic metastasis (case 7). At the hepatic metastasis, (A) MAGE family proteins were observed in both nuclei and
cytoplasm of tumour cells. No positive staining was observed in adjacent normal liver tissues ( 80). (B) High-power view of (A). Intense and
homogeneous staining was observed in almost all tumour cells ( 200). (C) MAGE-A10 mRNA signals were coincidently observed in MAGE family protein-
positive tumour cells ( 80). (D) High-power view of (C). They were abundant in the cytoplasm of tumour cells ( 200).
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in group C. Patients with MAGE-A protein and MAGE-A10 gene
expression had poor outcome (Po0.0001, each) (Figure 3A and
3B). Only three patients with MAGE-A10 gene expression survived
more than 5 years.
DISCUSSION
In this study, we have analysed MAGE-A protein expression by
immunohistochemistry using a monoclonal 6C1 antibody and
MAGE-A10 gene expression by ISH using a cRNA probe in
stomach cancer patients with and without liver metastasis. This is
the first report, to the best of our knowledge, that provides a new
insight into the expressions of the MAGE-A protein and MAGE-
A10 gene in patients with stomach cancer. The expression of both
was significantly higher in patients with liver metastasis than in
patients without liver metastasis. We also found that the
MAGE-A10 gene was frequently expressed in the primary and
metastatic lesions and was associated with a poor outcome.
In stomach cancer, MAGE-A protein expression was associated
with the stage and a worse prognosis, but not with distant organ
metastasis (Jung et al, 2005). MAGE-A1 gene expression has been
reported to be observed in the early stage of stomach cancer
(Katano et al, 1997). However, Honda et al (2004) reported that
demethylation in MAGE-A1 and -A3 promoters was much higher
in advanced clinical stages. Distant metastasis is an independent
prognostic factor in patients who have undergone surgical
resection (Siewert et al, 1998). Recurrence after complete resection
of stomach cancer occurs within 2 years and is fatal. Furthermore,
there was recurrence in distant sites in half of the patients and liver
metastasis was most frequent (D’Angelica et al, 2004). In this
study, most cases with both synchronous and metachronous liver
metastasis expressed the MAGE-A protein and MAGE-A10 gene in
both primary and metastatic lesions. Although the total number
was small in our series, two stage I patients who developed
metachronous liver metastasis expressed MAGE-A10 mRNA in the
primary lesions. It might be a predictive marker for metachronous
liver metastasis even in low-stage stomach cancers. On the other
hand, Alves et al (2007) reported that MAGE-A10 mRNA
expression was found in only 2 and 0% of the cases of primary
lesion and liver metastasis in colon cancer, respectively. We
assume that this discrepancy might be due to the differences in the
regulation of MAGE-A gene expression and the clinical outcome of
liver metastasis between these organs. These results emphasised
that expression of the MAGE-A genes might play an important role
in the progression of stomach cancer.
AFP-producing stomach cancer is highly malignant and has a
poor prognosis as the recurrent rate following curative resection is
high (Adachi et al, 2003). Amemiya et al (2005) reported that
c-Met overexpression was frequently detected in AFP-producing
stomach cancer, whereas Kataoka et al (2001) reported that the
absence of ATBF1 gene expression is responsible for AFP gene
expression. Recently, Cho et al (2007) reported that five of the
eight cancers with AFP expression showed genetic alterations of
the ATBF1 gene. In our study, all AFP-producing tumours
intensely expressed MAGE-A10 mRNA in the primary lesions.
However, the relationship between ATBF1 and MAGE genes and
AFP expression is still unknown. Taken together, these findings
suggested the aggressive nature of AFP-producing stomach cancer
accompanied with MAGE-A10 gene expression.
The function of MAGE family genes and proteins has not been
clearly elucidated. In the literature, MAGE-A1, -A2, -A3, -A5, -A6
and -A12 proteins were reported to act as oncoproteins (Yang et al,
2007), whereas MAGE-A4 protein was shown to act as an
oncosuppressor protein (Peikert et al, 2006). MAGE-A3 mRNA
expression was an independent poor prognostic marker in
adenocarcinoma of the lung (Gure et al, 2005). On the other
hand, MAGE-A4 mRNA expression correlated with a good clinical
outcome in non-small-cell lung cancer (Yoshida et al, 2006). Based
on our results, MAGE-A10 gene may participate in tumour
progression as an oncoprotein, although further analysis is needed.
In spite of significantly high concordance between MAGE-A
protein expression by 6C1 and MAGE-A10 gene expression by ISH
in our study, 11 cases (29.7%) out of 37 patients with positive
MAGE-A10 mRNA were negative for 6C1. Wang et al (2004)
reported that expression of NY-ESO-1 protein was lower than that
of NY-ESO-1 mRNA detected by RT–PCR. It was speculated
that immunohistochemical staining could not detect low-level
NY-ESO-1 protein expression. Intranuclear substances that are
immunohistochemically stained with the 6C1 antibody reflect the
MAGE-A10 protein (Rimoldi et al, 1999). In fact, our results
showed that both the nucleus and cytoplasm of the tumour cells
were stained in most 6C1-positive cases. We assume that this
discrepancy is mainly caused by the differences in sensitivity and
specificity between the two detection systems and target sites of the
sequence for a cRNA probe generated by PCR and the 6C1
monoclonal antibody.
The HLA-A2/MAGE-A10254 262 peptide is a good target for
active immunotherapy of malignant tumours such as melanoma,
hepatocellular carcinoma and lung cancer (Dutoit et al, 2001;
Bricard et al, 2005; Groeper et al, 2006). Dutoit et al (2001)
reported that only CTL could lyse MAGE-A10-expressing tumour
cells. In our experiments, MAGE-A10 expression was associated
with an advanced stage of stomach cancer. High incidence of
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Figure 3 Relationship between MAGE-A family protein (A) and MAGE-
A10 mRNA (B) expression and survival duration in all cases.
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metastatic lesions in hepatic metastasised patients. Thus, the
results of this study suggest that MAGE-A10 is a possible candidate
target in active immunotherapy for advanced stomach cancer.
Clinical trials of dendritic cell vaccine therapy using HLA-A2/
MAGE-A10254 262 peptide have been conducted (Chianese-Bullock
et al, 2005; Davis et al, 2006). In such an active immunotherapy,
the first step is the selection of patients suitable for the treatment.
The patients should be selected using immunohistochemical
analysis with 6C1 and assessment of MAGE-A10 gene expression
using highly sensitive ISH.
In summary, we clarified the role of MAGE-A10 gene expression
on tumour progression, especially liver metastasis in patients with
stomach cancer. Based on our methods, it could be possible to
select the patients for active immunotherapy using the MAGE-A10
peptide.
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